Cerveau subsidiary gets rights to Navidea's AD imaging agent

Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB; Tel Aviv:NAVB) granted the Meilleur Technologies Inc. subsidiary of Cerveau Technologies Inc. (Boston, Mass.) worldwide rights to conduct research using Alzheimer's disease imaging agent NAV4694, as well as an exclusive license to develop and commercialize the diagnostic tool in Australia, Canada, China and Singapore. Meilleur also has an option to commercialize NAV4694 worldwide. Financial terms were not disclosed...